3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Thyroid Neoplasms
1
Thoracic Neoplasms
1
Solid Tumors
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Advanced Thyroid Cancer Patients Who Received Target Therapy
1
Adenocarcinoma
1
Interventions
Carboplatin
7
Paclitaxel
4
Cisplatin
4
pembrolizumab
3
Pemetrexed
3
zipalertinib
2
selpercatinib
2
durvalumab
2
Nivolumab
2
Blood Specimen Collection
2
zimberelimab
1
taletrectinib
1
sotorasib
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
alectinib
1
Tomography, Emission-Computed, Single-Photon
1
Toll-Like Receptor 1
1
Telescopes
1
Surveys and Questionnaires
1
Radiosurgery
1
One-Lung Ventilation
1
Omacor
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Health Records, Personal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
pralsetinib
×
1 year
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts